Sanofi/GSK: VidPrevtyn Beta
Vaccine Type: Protein Subunit
This vaccine may also be referred to as CoV2 preS dTM adjuvanted vaccine (B.1.351), SP/GSK subunit B.1.351 vaccine
Vaccine Trial & Approval Tracker
-
Phase 1
-
Phase 2
-
Phase 3
-
Approved
This vaccine is approved.
About Trial Phases
Phase 1:
0
Trials
There are no trials for this phase.
Registered Trials
-
NCT05124171, EUCTR2021-004550-33
Phase 3
France
Total Enrollment: 300
Official Trial Registration:
-
NCT05405283
Phase 3
France
Total Enrollment: 178
Official Trial Registration:
-
NCT05518487
Phase 2
United States of America
Total Enrollment: 80
Official Trial Registration:
